BENLYSTA (GlaxoSmithKline Australia Pty Ltd)
Product name
BENLYSTA
Date registered
Evaluation commenced
Decision date
Approval time
197 (255 working days)
Active ingredients
Belimumab
Registration type
EOI
Indication
BENLYSTA is now also indicated for the treatment of active lupus nephritis in adult patients who are receiving standard therapy.